SCHEMBL18925496

SCHEMBL18925496

CN[C@@H](c1ccc(C)cc1)[C@@H](NC)c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.56
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ NFE2L2 Q16236 1/20 0.45
▸ LMNA P02545 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ HTR1A P08908 1/20 0.40
▸ HTR7 P34969 1/20 0.40
▸ HTR6 P50406 1/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ DRD2 P14416 1/20 0.37
▸ DRD4 P21917 1/20 0.37
▸ DRD3 P35462 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ CHRNA7 P36544 1/20 0.37
▸ SLC6A9 P48067 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17465587 0.91 CYP3A4 (0.52) ACHECYP3A4CYP2C19ALDH1A1HTT
SCHEMBL24016999 0.91 CYP3A4 (0.52) ACHECYP3A4CYP2C19ALDH1A1HTT
SCHEMBL24017007 0.91 CYP3A4 (0.52) ACHECYP3A4CYP2C19ALDH1A1HTT
SCHEMBL24017005 0.89 CYP3A4 (0.54) ACHECYP3A4CYP2C19NFE2L2LMNA
SCHEMBL13075238 0.80 CYP3A4 (0.41) ACHECYP3A4CYP2C19LMNAALDH1A1
SCHEMBL18925486 0.79 ACHE (0.52) ACHENFE2L2LMNAALDH1A1SMN1; SMN2
SCHEMBL24017143 0.78 ALDH1A1 (0.56) ACHECYP3A4CYP2C19NFE2L2LMNA
Dimethylamine SCHEMBL23675374 0.78 ACHE (0.81) ACHECYP3A4CYP2C19NFE2L2LMNA
SCHEMBL28077967 0.77 AOC3 (0.39) CYP3A4CYP2C19ALDH1A1HTTHDAC3
SCHEMBL20868149 0.77 ACHE (0.68) ACHENFE2L2LMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9862725-B2 Process for preparing chiral dipeptidyl peptidase-IV inhibitors MERCK SHARP & DOHME CORP. (US) 2018-01-09 — — US disclosed
US-20170158701-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME LLC 2017-06-08 — — US disclosed
US-20150272956-A1 SUBSTITUTED XANTHINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2015-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150272956-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 ACHE 945/4885CYP3A4 488/4885CYP2C19 892/4885
US-20170158701-A1 PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS DPP4, PEPD, DPP9 ACHE 2067/4885CYP3A4 149/4885CYP2C19 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback